New therapeutic agents marketed in 2018: Part 2

Activity Preview

Following our review of each new therapeutic agent, we compare the new drug with the older medication(s) with which it is most similar in properties and uses, and we identify advantages and disadvantages. Advantages and disadvantages are identified at the time the new drug is first marketed and do not reflect approval of additional new drugs and/or changes that occur after the drug is initially marketed.

Learning Objectives

At the completion of this activity, the pharmacist will be able to:

  1. Identify the new therapeutic agents and explain their appropriate use.
  2. Identify the indications and mechanisms of action of the new agents.
  3. Identify the most important adverse events and other risks of the new agents.
  4. State the route of administration for each new drug and the most important considerations regarding dosage and administration.
  5. Compare the new therapeutic agents with older medications to which they are most similar in properties and/or use, and identify the most important advantages and disadvantages of the new drugs.

Activity type: Knowledge-based

Target Audience: Pharmacists & Pharmacy Technicians

Learning level: 1

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-18-264-H01-P.

To obtain credit for New therapeutic agents marketed in 2018: Part 2 complete the assessment with a grade of 70% or better, complete the evaluation, and then claim credit. Participants need to have a valid username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.

APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted.  The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: November 1, 2018
Expiration date: November 1, 2021 - NO CREDIT GRANTED AFTER THIS DATE


New therapeutic agents marketed in 2018: Part 2 is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.

Advisory Board

Daniel A. Hussar, PhD

Dean Emeritus and Remington Professor of Pharmacy Emeritus

Philadelphia College of Pharmacy at the University of the Sciences, Philadelphia

600 S. 43rd St., Philadelphia, PA 19104-4495;

Eric F. Hussar, MD

Primary care physician, Susquehanna Family Medicine, Marietta, PA

Mark S. Johnson, PharmD, BCPS 

Professor, Department of Pharmacy Practice and Director of Postgraduate Education

Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA


Mark S. Johnson, PharmD, BCPS, declares that he and his spouse hold stock in Merck & Co.

Daniel A. Hussar, PhD, FAPhA; Eric F. Hussar, MD; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at


There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website and view the Technology System Requirements to have a positive learning experience.